K-numberK243836
Device nameMentor™ CPX ™ 4 PLUS Enhance Breast Tissue Expander
ApplicantMentor Worldwide, LLC
Product codeLCJ
Device classClass U
Decision dateJan 12, 2025
DecisionSubstantially Equivalent
Regulation
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The Mentor CPX 4 PLUS Enhance Breast Tissue Expander is a temporary subcutaneous or submuscular implant used for breast reconstruction following mastectomy, correction of underdeveloped breasts, scar revision, and tissue defect procedures. The device consists of a silicone elastomer shell with an integral injection dome and self-sealing technology (BUFFERZONE), designed to be filled incrementally with saline solution over up to six months of use.

Technological characteristics

The device features a smooth silicone elastomer shell with superior and anterior reinforcement for directional expansion in the lower pole, an integral magnetically-detected injection dome with a rare-earth permanent magnet, and BUFFERZONE self-sealing gel technology to prevent leakage from accidental needle puncture. It is provided sterile and deflated with fill volume options from 850 cc to 1445 cc, identical in all materials and patient-contact components to the predicate device.

Test standards cited

ASTM F1441-03 Standard Specification for Soft-Tissue Expanders was used for mechanical testing including overexpansion and bladder leak testing. ISO 10993-1:2018 was referenced for biocompatibility contact categorization as an implant with tissue contact for greater than 30 days.

Substantial equivalence argument

Substantial equivalence is established because the proposed device has identical materials, design features, and specifications to the predicate K241918, with no changes to components, mechanical properties, or biocompatibility. The only modification is expanding the lower fill volume limit from 930 cc to 850 cc to align with predicate K152496; since mechanical testing previously demonstrated the device meets performance criteria at the worst-case volume of 1445 cc, reducing the lower limit does not require additional testing and does not affect safety or effectiveness.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →